skip to main |
skip to sidebar
ACIP | Home | Advisory Committee on Immunization Practices | CDC
ACIP | Home | Advisory Committee on Immunization Practices | CDC
ACIP Votes, October 2016
- ACIP approved the following four recommendations by majority vote on October 19, 2016:
- Hepatitis B vaccine: birth dose within 24 hours of birth for medically stable infants weighing ≥2000 grams and born to HBsAg-negative mothers; removal of permissive language to delay the hepatitis B birth dose; approve revised statement.
- Human papillomavirus vaccine: 2-dose schedule for boys and girls initiating HPV vaccination series at 9 to 14 years (0,6-12 months); 3-dose schedule for persons initiating HPV vaccination series at older ages; 3-dose schedule for immunocompromised persons.
- Meningococcal vaccines: provided guidance on the updated dosing schedules for one serogroup B meningococcal vaccine, MenB-FHbp (Trumenba). For persons at increased risk for meningococcal disease and during serogroup B outbreaks, 3 doses of MenB-FHbp administered at 0, 1-2, and 6 months; when given to healthy adolescents not at increased risk for meningococcal disease, 2 doses of MenB-FHbp at 0 and 6 months.
- Pertussis-containing vaccines: approve the updated statement, “Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the ACIP.”
- The 2017 Child/Adolescent and Adult Immunization schedules were approved by majority vote on October 20, 2016.
- If approved by the CDC Director, the recommendations will become official once published in MMWR.
No hay comentarios:
Publicar un comentario